Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.35Last Year’s EPS
-1.12Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.Company Guidance
Two Partner Programs Advanced to Phase III
Roche advanced prasinezumab into the Phase III PARAISO trial (≈900 participants; primary completion expected in 2029). Novo Nordisk advanced coramitug into the Phase III CLEOPATTRA trial (≈1,280 patients; primary completion expected in 2029).
Strong Phase II Biomarker and Clinical Signals
Prasinezumab exploratory subset (patients on levodopa) showed a 40% relative reduction in MDS‑UPDRS Part III progression (nominal p=0.0177). Coramitug 60 mg/kg produced a 48% reduction in NT‑proBNP versus placebo (p=0.0017) and echocardiographic improvements suggestive of cardiac remodeling.
Robust Financial Position vs. Guidance
Year‑end 2025 cash and restricted cash of $308.4M (favorable to guidance of $298M). Net cash used in operating and investing activities was $163.7M (favorable to guidance $170M–$178M). Net loss of $244.1M was in line with guidance ($240M–$248M).
Material Near‑Term and Long‑Term Upside from Partnered Programs
Potential to earn up to $105M in aggregate clinical milestone payments in 2026 tied to coramitug enrollment targets and a BMS decision on PRX019. Aggregate partner programs could deliver up to approximately $3.0B in future milestone payments (in addition to royalties).
CYTOPE Platform and TDP‑43 Preclinical Progress
Introduced CYTOPE technology and presented TDP‑43 CYTOPE data showing systemic CNS activity in aggressive ALS mouse models, reduction of brain and muscle pathology, and attenuation of RNA mis‑splicing—supporting intracellular targeting capability.
PRX012 Clinical Activity Demonstrated
ASCENT Phase I interim results: mean amyloid PET reduction to ~27.5 centiloids at 12 months for patients on monthly 400 mg subcutaneous PRX012; preliminary 18‑month mean centiloid ≈16 with 9 of 12 patients (75%) achieving amyloid negativity (<24.1 centiloids).
Partnership and Development Momentum
BMS completed full enrollment in Phase II TargetTau‑1 (~310 patients) with primary completion expected H1 2027; BMS‑986446 received FDA Fast Track designation. Ongoing research collaboration(s) for CYTOPE with a large pharmaceutical company. Company approved for a 2026 share redemption program by shareholders and Irish High Court.
PRTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PRTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 19, 2026 | $9.03 | $9.02 | -0.11% |
Nov 06, 2025 | $10.08 | $10.56 | +4.76% |
Aug 04, 2025 | $6.94 | $7.03 | +1.30% |
May 08, 2025 | $7.10 | $7.43 | +4.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Prothena (PRTA) report earnings?
Prothena (PRTA) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Prothena (PRTA) earnings time?
Prothena (PRTA) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRTA EPS forecast?
PRTA EPS forecast for the fiscal quarter 2026 (Q1) is -0.35.